Dr. Zandberg on Biomarker Development in Head and Neck Cancer

Dan Zandberg, MD
Published: Tuesday, Oct 17, 2017



Dan Zandberg, MD, assistant professor of medicine, the University of Maryland School of Medicine, discusses biomarker development in patients with head and neck cancer.

Biomarkers are important for determining which immunotherapy regimen a patient should receive, says Zandberg. Currently, in head and neck cancer there has not been an identified biomarker to predict response to these therapies.
 
SELECTED
LANGUAGE


Dan Zandberg, MD, assistant professor of medicine, the University of Maryland School of Medicine, discusses biomarker development in patients with head and neck cancer.

Biomarkers are important for determining which immunotherapy regimen a patient should receive, says Zandberg. Currently, in head and neck cancer there has not been an identified biomarker to predict response to these therapies.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How Can We Optimize Outcomes in Head and Neck Cancers with Immunotherapeutic Strategies?Oct 31, 20191.5
Advances in™ Biomarkers: How Can I Utilize Tumor Mutational Burden in My Practice?Nov 30, 20191.5
Publication Bottom Border
Border Publication
x